Price movement over the last 24 hours
ARK Genomic Revolution ETF vs YieldMax NVDA Option Income Strategy ETF — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while YieldMax NVDA Option Income Strategy ETF trades at $12.66. The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | NVDY | |
|---|---|---|
Sector | Sector/Thematic | Income / Options Overlay |
52-Week High | $43.57 | $17.96 |
52-Week Low | $23.09 | $12.03 |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $12.75, up 2.66% today, amid a bearish technical signal. The fund generates weekly dividends from selling options on NVIDIA stock, with recent payouts ranging from $0.10 to $0.21. Key support sits at $12, resistance at $13, while RSI readings are neutral but ADX indicates a strong downtrend. News highlights focus on the trade-off between income and missing NVIDIA's upside potential.
Outlook hinges on NVIDIA's volatility sustaining option premiums, offering high yield but capped gains. Risks include underperformance if NVIDIA rallies sharply and reliance on options strategy execution. The fund appeals to income-focused investors willing to sacrifice growth for distributions, with sentiment mixed due to opportunity cost concerns.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →